NCT04972396View on ClinicalTrials.gov

Pemvidutide (ALT-801) DDI Study in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 15, 2021

Primary Completion Date

May 15, 2022

Study Completion Date

May 15, 2022

Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
DRUG

Pemvidutide

Injected subcutaneously (SC)

DRUG

Metformin

Taken by mouth (PO)

DRUG

Atorvastatin

Taken by mouth (PO)

DRUG

Warfarin

Taken by mouth (PO)

DRUG

Digoxin

Taken by mouth (PO)

DRUG

Ethinylestradiol and Levonorgestrel

Taken by mouth (PO)

Trial Locations (2)

Unknown

CMAX Clinical Research, Adelaide

Nucleus Network, Brisbane

Sponsors

Lead Sponsor

Altimmune, Inc.
All Listed Sponsors
lead

Altimmune, Inc.

INDUSTRY

NCT04972396 - Pemvidutide (ALT-801) DDI Study in Healthy Volunteers | Biotech Hunter | Biotech Hunter